P3 Health Partners Inc. (PIII) Q4 2025 Earnings Call Transcript

P3 Health held its Q4 2025 earnings conference call on March 26, 2026 (4:30 PM EDT); the provided excerpt contains only opening remarks and no reported financial results or guidance. Management (CEO Aric Coffman, CMO Amir Bacchus, CFO Leif Pedersen) and IR Gabriella Gabel emphasized forward-looking disclosures and risk factors and referenced non-GAAP measures including adjusted operating expense, adjusted EBITDA (and per-member metrics), medical margin (and per-member metrics), normalized adjusted EBITDA, and cash flow. Analysts on the call included Ryan Langston (TD Cowen) and Joshua Raskin (Nephron Research). Routine opening remarks without metrics — unlikely to move the stock absent subsequent data or guidance.

Analysis

P3’s model is levered to membership scale and medical-margin conversion; the non-obvious winners are vendors and partners that reduce per-member variable cost (behavioral health networks, home-based care suppliers, virtual specialty consult platforms). If P3 can shave $5–10 PMPM in medical spend via tighter referral management and more virtual-first care, that flows almost directly to adjusted EBITDA given the high fixed-cost absorption of their infrastructure — meaning relatively small clinical efficiencies can produce outsized margin moves in 6–18 months.

Key second-order risks are operational: workforce supply (primary care clinicians, care managers) and contract churn with large payors. A 5–10% clinician productivity hit or a single large plan not renewing could reverse a quarter or two of margin gains quickly; conversely, multi-year capitated deals lock in upside but raise exposure to actuarial miss. Macro and regulatory noise (Medicaid enrollment redeterminations, state rate changes) create 3–12 month volatility windows that can swamp execution signals.

From a competitive standpoint, incumbent payors and vertically integrated players (insurers with large primary care investments) are the structural threat — they can replicate care-pathway changes but are slower to reprice. That makes P3 a short-duration, catalyst-driven idea: if execution and enrollment cadence read cleanly over the next two earnings, upside compresses valuation gaps; if not, downside is rapid. Our base-case view is that near-term option exposures capture the asymmetry better than naked equity until we see sustained margin conversion over two consecutive quarters.

Key Decisions for Investors

• Tactical long (PIII): Buy PIII equity sized to risk budget and hedge with a 6–9 month 25% OTM protective put to cap downside to ~15–20% while retaining most upside if membership/margin progress continues. Timeframe: 6–12 months. R/R: asymmetric — limited defined downside vs potential 50–100% upside on successful scale.
• Structured options (PIII): Buy a 9–12 month call spread (buy ATM call / sell 30–40% OTM call) to express a constructive view while funding premium; target entry on any >10% post-quarter selloff. Timeframe: 9–12 months. R/R: lower cost with 2–3x potential on premium if catalysts validate.
• Hedge pair: Long PIII / Short UNH (or large-cap insurer) sized 1:0.8 to strip market beta and isolate execution; use this into the next 2 earnings prints to play idiosyncratic operational beats. Timeframe: 3–6 months. R/R: profitable if P3’s margin conversion exceeds that of broad insurers; limits macro-driven moves.
• Event short (PIII): Buy 3-month puts as a binary hedge ahead of enrollment/regulatory milestones or a guidance update if signs point to churn or workforce pressure. Timeframe: days–weeks around catalysts. R/R: low-cost tail protection that pays off on sharp downside catalysts.